MYC and neoplasm: In addition, in MYC-overexpressed breast tumour models, metformin combined with anti-apoptotic B-cell lymphoma-2 inhibitors, navitoclax or venetoclax, led to tumour growth inhibition, improved clinical outcomes and tumour infiltration by immune cells [124].